162 related articles for article (PubMed ID: 18047466)
21. [Hormone therapy as a therapeutic option in prevention of restenosis after angioplasty? Analysis of estrogen and progesterone receptors in human coronary plaque cells in vitro].
Voisard R; Seitzer U; Hannekum A; Kochs M; Hombach V; Böhm W
Vasa Suppl; 1992; 35():130-1. PubMed ID: 1481016
[No Abstract] [Full Text] [Related]
22. Arterial smooth muscle injury causes blood tissue factor elevation predicting restenosis after pci.
Li S; Zhang S; Li N; Li Z; Yu B; Tian Y
Scand Cardiovasc J; 2012 Apr; 46(2):87-92. PubMed ID: 22204555
[TBL] [Abstract][Full Text] [Related]
23. [The role of matrix metal proteinases in the development of restenoses after transcutaneous coronary interventions].
Zemlianskaia OA
Angiol Sosud Khir; 2004; 10(2):29-35. PubMed ID: 15163966
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel-eluting balloon: from bench to bed.
De Labriolle A; Pakala R; Bonello L; Lemesle G; Scheinowitz M; Waksman R
Catheter Cardiovasc Interv; 2009 Apr; 73(5):643-52. PubMed ID: 19309715
[TBL] [Abstract][Full Text] [Related]
25. Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Jimenez-Valero S; Moreno R; Sanchez-Recalde A; Galeote G; Calvo L; Viana A; Lopez de Sá E; López-Sendón J
Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):137-46. PubMed ID: 19124417
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
27. Local delivery of 17-beta-estradiol modulates collagen content in coronary porcine arteries after PTCA and stent implantation.
Geraldes P; Geoffroy P; Cloutier I; Sirois MG; Tanguay JF
J Vasc Res; 2008; 45(6):503-11. PubMed ID: 18451633
[TBL] [Abstract][Full Text] [Related]
28. Review of percutaneous therapy for bifurcation lesions in the era of drug-eluting stents.
Pendyala L; Jabara R; Hou D; Shinke T; Li J; Gadesam R; Robinson K; Chronos N; Chen JP
Minerva Cardioangiol; 2008 Feb; 56(1):89-105. PubMed ID: 18432172
[TBL] [Abstract][Full Text] [Related]
29. Vascular injury and modulation of MAPKs: a targeted approach to therapy of restenosis.
Yu PJ; Ferrari G; Pirelli L; Gulkarov I; Galloway AC; Mignatti P; Pintucci G
Cell Signal; 2007 Jul; 19(7):1359-71. PubMed ID: 17448633
[TBL] [Abstract][Full Text] [Related]
30. Celecoxib and hypertension-insights from the effect of celecoxib on restenosis after coronary angioplasty with a taxus stent trial.
Bangalore S; Khianey S; Messerli FH
Am J Cardiol; 2008 Apr; 101(7):1068. PubMed ID: 18359335
[No Abstract] [Full Text] [Related]
31. p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity.
van Tiel CM; Bonta PI; Rittersma SZ; Beijk MA; Bradley EJ; Klous AM; Koch KT; Baas F; Jukema JW; Pons D; Sampietro ML; Pannekoek H; de Winter RJ; de Vries CJ
Circulation; 2009 Aug; 120(8):669-76. PubMed ID: 19667240
[TBL] [Abstract][Full Text] [Related]
32. Reprogramming the cell cycle machinery to treat cardiovascular disease.
Bicknell KA; Brooks G
Curr Opin Pharmacol; 2008 Apr; 8(2):193-201. PubMed ID: 18243794
[TBL] [Abstract][Full Text] [Related]
33. Long term results of unprotected left main percutaneous coronary intervention with DES versus BMS.
Capodanno D; Di Salvo ME; Capranzano P; Seminara D; Caggegi A; Barrano G; Tamburino C
Minerva Cardioangiol; 2009 Feb; 57(1):1-6. PubMed ID: 19202514
[TBL] [Abstract][Full Text] [Related]
34. Alpha particle vascular brachytherapy in the treatment of in-stent Restenosis.
Mehdizadeh A; Fazelzadeh A; Karimi H
Int J Cardiol; 2009 Aug; 136(2):220-1. PubMed ID: 18625530
[TBL] [Abstract][Full Text] [Related]
35. Bifurcation coronary artery disease: current techniques and future directions (part 2).
Rizik DG; Klassen KJ; Hermiller JB
J Invasive Cardiol; 2008 Mar; 20(3):135-41. PubMed ID: 18316830
[No Abstract] [Full Text] [Related]
36. Percutaneous coronary interventions and statins therapy.
Nusca A; Melfi R; Di Sciascio G
Ther Adv Cardiovasc Dis; 2008 Apr; 2(2):101-7. PubMed ID: 19124413
[TBL] [Abstract][Full Text] [Related]
37. Covered stents: a review.
Jamshidi P; Mahmoody K; Erne P
Int J Cardiol; 2008 Nov; 130(3):310-8. PubMed ID: 18672301
[TBL] [Abstract][Full Text] [Related]
38. Restenosis is not associated with stent length in a pig model of coronary stent implantation.
Koutouzis M; Papalois A; Kyrzopoulos S; Dafnomili P; Kyriakides ZS
Cardiol J; 2008; 15(5):458-62. PubMed ID: 18810722
[TBL] [Abstract][Full Text] [Related]
39. Coronary artery stents: Part I. Evolution of percutaneous coronary intervention.
Newsome LT; Kutcher MA; Royster RL
Anesth Analg; 2008 Aug; 107(2):552-69. PubMed ID: 18633035
[TBL] [Abstract][Full Text] [Related]
40. Frugal coronary angioplasty, still an option after 30 years.
Meier B
J Invasive Cardiol; 2008 Apr; 20(4):E97-101. PubMed ID: 18398248
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
